# A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

> **NCT02806960** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Nasal Glucagon

## Key facts

- **NCT ID:** NCT02806960
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Drug delivery was below target dose due to partial obstruction by aggregated particles.
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806960, "A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02806960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*